fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Invega Hayfera (6-month paliperidone palmitate), first and only twice-yearly treatment for adults with schizophrenia – Janssen Pharmaceuticals

Written by | 24 Sep 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.

Predicting possible Alzheimer’s with nearly 100 percent accuracy

Written by | 8 Sep 2021

Researchers from Kaunas universities, Lithuania developed a deep learning-based method that can predict the possible onset of Alzheimer’s disease from brain images with an accuracy of over 99… read more.

An open letter to the Alzheimer’s disease community from Biogen Head of Research and Development, Alfred Sandrock, M.D., Ph.D

Written by | 27 Jul 2021

Statement from Head of Research and Development, Alfred Sandrock, M.D., Ph.D.:Biogen Inc. – On June 7, 2021, Aduhelm became the first approved treatment to address a defining pathology… read more.

One in four women with ADHD has attempted suicide

Written by | 5 Jan 2021

Attention Deficit Hyperactive Disorder (ADHD) can have negative consequences on mental health into adulthood.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.